Literature DB >> 17913803

Overexpression of the kaposi's sarcoma-associated herpesvirus transactivator K-Rta can complement a K-bZIP deletion BACmid and yields an enhanced growth phenotype.

Taeko Kato-Noah1, Yiyang Xu, Cyprian C Rossetto, Kelly Colletti, Iva Papousková, Gregory S Pari.   

Abstract

Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (HHV8) ORF50 encodes a transactivator, K-Rta, which functions as the switch from latent to lytic virus replication. K-bZIP interacts with K-Rta and can repress its transactivation activity for some viral promoters. Both K-Rta and K-bZIP are required for origin-dependent DNA replication. To determine the role of K-bZIP in the context of the viral genome, we generated a recombinant HHV8 bacterial artificial chromosome (BAC) with a deletion in the K-bZIP open reading frame. This BACmid, BAC36DeltaK8, displayed an enhanced growth phenotype with respect to virus production and accumulation of virus-encoded mRNAs measured by real-time PCR when K-Rta was used to induce the virus lytic cycle. Conversely, induction of the virus lytic cycle using tetradecanoyl phorbol acetate/n-butyrate resulted in no virus production and an aberrant gene expression pattern from BAC36DeltaK8-containing cells compared to wild-type (wt) BAC. This null virus phenotype was efficiently complemented by the expression of K-bZIP in trans, restoring virus production to wt BAC levels. Immunofluorescence staining revealed that subcellular localization of K-Rta was unchanged; however, a disruption of LANA subcellular localization was observed in cells harboring BAC36DeltaK8, suggesting that K-bZIP influences LANA localization. Coimmunoprecipitation experiments confirmed that K-bZIP interacts with LANA in BCBL-1 cells and in cotransfection assays. Lastly, the chromatin immunoprecipitation assay revealed that, in an environment where K-Rta is overexpressed and in the absence of K-bZIP, K-Rta binds to CAAT enhancer binding protein alpha sites within oriLyt, suggesting that it is K-Rta that supplies an essential replication function and that K-bZIP may serve to augment or facilitate the interaction of K-Rta with oriLyt.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913803      PMCID: PMC2168825          DOI: 10.1128/JVI.00832-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Evaluation of the lytic origins of replication of Kaposi's sarcoma-associated virus/human herpesvirus 8 in the context of the viral genome.

Authors:  Yiyang Xu; Alicia Rodriguez-Huete; Gregory S Pari
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication.

Authors:  Yiyang Xu; David P AuCoin; Alicia Rodriguez Huete; Sylvia A Cei; Lisa J Hanson; Gregory S Pari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Two subclasses of Kaposi's sarcoma-associated herpesvirus lytic cycle promoters distinguished by open reading frame 50 mutant proteins that are deficient in binding to DNA.

Authors:  Pey-Jium Chang; Duane Shedd; George Miller
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification.

Authors:  Yoshihiro Izumiya; Thomas J Ellison; Edward T H Yeh; Jae U Jung; Paul A Luciw; Hsing-Jien Kung
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus lytic gene ORF57 is essential for infectious virion production.

Authors:  Zhao Han; Sankar Swaminathan
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus lytic origin (ori-Lyt)-dependent DNA replication: identification of the ori-Lyt and association of K8 bZip protein with the origin.

Authors:  Cui Li Lin; Hong Li; Yan Wang; Fan Xiu Zhu; Sagar Kudchodkar; Yan Yuan
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency.

Authors:  Ke Lan; Daniel A Kuppers; Subhash C Verma; Nikhil Sharma; Masanao Murakami; Erle S Robertson
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  K-bZIP of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) binds KSHV/HHV-8 Rta and represses Rta-mediated transactivation.

Authors:  Wei Liao; Yong Tang; Su-Fan Lin; Hsing-Jien Kung; Chou-Zen Giam
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Cell cycle regulation by Kaposi's sarcoma-associated herpesvirus K-bZIP: direct interaction with cyclin-CDK2 and induction of G1 growth arrest.

Authors:  Yoshihiro Izumiya; Su-Fang Lin; Thomas J Ellison; Alon M Levy; Greg L Mayeur; Chie Izumiya; Hsing-Jien Kung
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Kaposi's sarcoma-associated herpesvirus K-bZIP is a coregulator of K-Rta: physical association and promoter-dependent transcriptional repression.

Authors:  Yoshihiro Izumiya; Su-Fang Lin; Thomas Ellison; Ling-Yu Chen; Chie Izumiya; Paul Luciw; Hsing-Jien Kung
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  22 in total

1.  Interaction of Kaposi's sarcoma-associated herpesvirus ORF59 with oriLyt is dependent on binding with K-Rta.

Authors:  Cyprian C Rossetto; Ni Ketut Susilarini; Gregory S Pari
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  A comprehensive analysis of recruitment and transactivation potential of K-Rta and K-bZIP during reactivation of Kaposi's sarcoma-associated herpesvirus.

Authors:  Thomas J Ellison; Yoshihiro Izumiya; Chie Izumiya; Paul A Luciw; Hsing-Jien Kung
Journal:  Virology       Date:  2009-03-09       Impact factor: 3.616

Review 3.  Virion factors that target Daxx to overcome intrinsic immunity.

Authors:  Sabrina Schreiner; Harald Wodrich
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

4.  Histone demethylase JMJD2A regulates Kaposi's sarcoma-associated herpesvirus replication and is targeted by a viral transcriptional factor.

Authors:  Pei-Ching Chang; Latricia D Fitzgerald; Datsun A Hsia; Yoshihiro Izumiya; Chun-Yi Wu; Wen-Ping Hsieh; Su-Fang Lin; Mel Campbell; Kit S Lam; Paul A Luciw; Clifford G Tepper; Hsing-Jien Kung
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

5.  Nucleocytoplasmic shuttling of human cytomegalovirus UL84 is essential for virus growth.

Authors:  Yang Gao; Dominique Kagele; Kate Smallenberg; Gregory S Pari
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

6.  Kaposi's Sarcoma-Associated Herpesvirus K8 Is an RNA Binding Protein That Regulates Viral DNA Replication in Coordination with a Noncoding RNA.

Authors:  Dongcheng Liu; Yan Wang; Yan Yuan
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

7.  Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism.

Authors:  Andrew J Rennekamp; Paul M Lieberman
Journal:  Future Virol       Date:  2010-01       Impact factor: 1.831

8.  Leucine zipper domain is required for Kaposi sarcoma-associated herpesvirus (KSHV) K-bZIP protein to interact with histone deacetylase and is important for KSHV replication.

Authors:  Francisco Puerta Martínez; Qiyi Tang
Journal:  J Biol Chem       Date:  2012-03-13       Impact factor: 5.157

9.  Functional characterization of Kaposi's sarcoma-associated herpesvirus open reading frame K8 by bacterial artificial chromosome-based mutagenesis.

Authors:  Yan Wang; Narayanan Sathish; Charles Hollow; Yan Yuan
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

10.  Kaposi's sarcoma-associated herpesvirus K-bZIP protein is necessary for lytic viral gene expression, DNA replication, and virion production in primary effusion lymphoma cell lines.

Authors:  Sylvain Lefort; Louis Flamand
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.